Literature DB >> 26745487

Malignant peripheral nerve sheath tumors of the eighth cranial nerve arising without prior irradiation.

Matthew L Carlson1, Jeffrey T Jacob2, Elizabeth B Habermann3, Amy E Glasgow3, Aditya Raghunathan4, Michael J Link1,2.   

Abstract

OBJECTIVE Malignant peripheral nerve sheath tumors (MPNSTs) of the eighth cranial nerve (CN) are exceedingly rare. To date the literature has focused on MPNSTs occurring after radiation therapy for presumed benign vestibular schwannomas (VSs), while MPNSTs arising without prior irradiation have received little attention. The objectives of the current study are to characterize the epidemiology, clinical presentation, disease course, and outcome using a large national cancer registry database and a systematic review of the English literature. Additionally, a previously unreported case is presented. METHODS The authors conducted an analysis of the Surveillance, Epidemiology, and End Results (SEER) database, a systematic review of the literature, and present a case report. Data from all patients identified in the SEER database with a diagnosis of MPNST involving the eighth CN, without a history of prior radiation, were analyzed. Additionally, all cases reported in the English literature between January 1980 and March 2015 were reviewed. Finally, 1 previously unreported case is presented. RESULTS The SEER registries identified 30 cases between 1992 and 2012. The average incidence was 0.017 per 1 million persons per year (range 0.000-0.0687 per year). The median age at diagnosis was 55 years, and 16 (53%) were women. Thirteen cases were diagnosed upon autopsy. Of the 17 cases diagnosed while alive, the median follow-up was 118 days, with 3 deaths (18%) observed. When compared with the incidence of benign VS, 1041 VSs present for every 1 MPNST arising from the eighth CN. Including a previously unreported case from the authors' center, a systematic review of the English literature yielded 24 reports. The median age at diagnosis was 44 years, 50% were women, and the median tumor size at diagnosis was 3 cm. Eleven patients (46%) reported isolated audiovestibular complaints typical for VS while 13 (54%) exhibited facial paresis or other signs of a more aggressive process. Treatment included microsurgery alone, microsurgery with adjuvant radiation, or microsurgery with chemoradiation. Sixty-one percent of patients receiving treatment experienced recurrence, 22% of which were diagnosed with drop metastases to the spine. Ultimately, 13 patients (54%) died of progressive disease at a median of 3 months following diagnosis. The ability to achieve gross-total resection was the only feature that was associated with improved disease-specific survival. CONCLUSIONS MPNSTs of the eighth CN are extremely rare and portend a poor prognosis. Nearly half of patients initially present with findings consistent with a benign VS, often making an early diagnosis challenging. In light of these data, early radiological and clinical follow-up should be considered in those who elect nonoperative treatment, particularly in patients with a short duration of symptoms or atypical presentation. These data also provide a baseline rate of malignancy that should be considered when estimating the risk of malignant transformation following stereotactic radiosurgery for VS.

Entities:  

Keywords:  CN = cranial nerve; GTR = gross-total resection; Gamma Knife radiosurgery; ICD-O-3 = International Classification of Diseases for Oncology-Third Edition; MPNST = malignant peripheral nerve sheath tumors; NF, NF1, NF2 = neurofibromatosis, NF Type 1, NF Type 2; NOS = not otherwise specified; NTR = near-total resection; SEER = Surveillance, Epidemiology, and End Results; STR = subtotal resection; VS = vestibular schwannoma; acoustic neuroma; cerebellopontine angle; epithelioid schwannoma; malignant; melanocytic schwannoma; microsurgery; neurofibrosarcoma; oncology; peripheral nerve sheath tumor; stereotactic radiosurgery; vestibular schwannoma

Mesh:

Year:  2016        PMID: 26745487     DOI: 10.3171/2015.7.JNS151056

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  8 in total

1.  Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo.

Authors:  Sherif G Ahmed; Ahmed Abdelnabi; Casey A Maguire; Mohamed Doha; Jessica E Sagers; Rebecca M Lewis; Alona Muzikansky; Marco Giovannini; Anat Stemmer-Rachamimov; Konstantina M Stankovic; Giulia Fulci; Gary J Brenner
Journal:  Neuro Oncol       Date:  2019-07-11       Impact factor: 12.300

Review 2.  Ear and Temporal Bone Pathology: Neural, Sclerosing and Myofibroblastic Lesions.

Authors:  A N Flaman; J K Wasserman; D H Gravel; B M Purgina
Journal:  Head Neck Pathol       Date:  2018-08-01

Review 3.  Transition of a vestibular schwannoma to a malignant peripheral nerve sheath tumor with loss of H3K27 trimethylation after radiosurgery-a case report and review of the literature.

Authors:  Felix Behling; Imane Bersali; Antonio Santacroce; Johann Hempel; Kosmas Kandilaris; Jens Schittenhelm; Marcos Tatagiba
Journal:  Neurosurg Rev       Date:  2021-08-15       Impact factor: 2.800

4.  EANO guideline on the diagnosis and treatment of vestibular schwannoma.

Authors:  Roland Goldbrunner; Michael Weller; Jean Regis; Morten Lund-Johansen; Pantelis Stavrinou; David Reuss; D Gareth Evans; Florence Lefranc; Kita Sallabanda; Andrea Falini; Patrick Axon; Olivier Sterkers; Laura Fariselli; Wolfgang Wick; Joerg-Christian Tonn
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

5.  Neurofibromatosis type I with malignant peripheral nerve sheath tumors in the upper arm: A case report.

Authors:  Lili Zhang; Fangfang Sun; Hongyu Li; Jie Du; Lirong Zhao
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

6.  Genetic alterations associated with malignant transformation of sporadic vestibular schwannoma.

Authors:  Morten Lund-Johansen; Per-Morten Knappskog; Aril Løge Håvik; Ove Bruland; Hrvoje Miletic; Lars Poulsgaard; David Scheie; Kåre Fugleholm
Journal:  Acta Neurochir (Wien)       Date:  2021-11-24       Impact factor: 2.216

7.  Malignant Transformation in Vestibular Schwannoma: Clinical Study With Survival Analysis.

Authors:  Jiuhong Li; Qiguang Wang; Menglan Zhang; Guisheng Zhang; Si Zhang; Xuhui Hui
Journal:  Front Oncol       Date:  2021-04-14       Impact factor: 6.244

8.  Schwannoma Gene Therapy via Adeno-Associated Viral Vector Delivery of Apoptosis-Associated Speck-like Protein Containing CARD (ASC): Preclinical Efficacy and Safety.

Authors:  Sherif G Ahmed; Casey A Maguire; Shiliang Alice Cao; Gary J Brenner
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.